A Phase I Neoadjuvant Study of In-situ REIC/Dkk-3 Therapy Followed By Prostatectomy in Patients With High Risk Localized Prostate Cancer.

Trial Profile

A Phase I Neoadjuvant Study of In-situ REIC/Dkk-3 Therapy Followed By Prostatectomy in Patients With High Risk Localized Prostate Cancer.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 26 Jun 2015

At a glance

  • Drugs Ad5 SGE DKK3 gene therapy-Momotaro (Primary)
  • Indications Mesothelioma; Prostate cancer
  • Focus Adverse reactions
  • Sponsors Momotaro-Gene
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Aug 2013 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov record.
    • 22 Jun 2011 Planned end date changed from Nov 2011 to Nov 2012 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top